Figure 1.

Tumor expression of Ido1 in KPC PDAC models requires an intact immune system in vivo

(A) Schematic diagram detailing the methods used to analyze Ido1 expression in mouse models of PDAC.

(B and C) Tumors from Pdx1-Cre;Kras^G12D/+;Trp53^fl/+ and Pdx1-Cre;Kras^G12D/+;Trp53^R172H/+ mice and healthy pancreas tissue from non-Cre-expressing isogenic control mice analyzed by western blots (B) quantified using a Li-Cor infrared scanner (C) (healthy pancreas n = 5, Pdx1-Cre;Kras^G12D/+;Trp53^fl/+ tumors n = 6, Pdx1-Cre;Kras^G12D/+;Trp53^R172H/+ tumors n = 5, p values calculated with unpaired 2-sided t test, bars are SDs).

(D) KPC cell line isolated from a mixed-background Pdx1-Cre;Kras^G12D/+;Trp53^R172H/+ tumor was either grown in vitro culture (with or without human or mouse IFNγ (1 ng/mL) for 24 h), or subcutaneously injected into the flank of CD1-nude mice to form tumors. Cell and tumor lysates were analyzed for the indicated proteins.

(E) Three KPC cell lines isolated from C57Bl6/J Pdx1-Cre;Kras^G12D/+;Trp53^R172H/+ mice were injected into the flanks of C57Bl6/J mice or CD-1-nude mice to form tumors. Cell and tumor lysates were analyzed for the indicated proteins.

(F) Survival data for human pancreatic cancer patients from TCGA was downloaded from The Human Protein Atlas (https://www.proteinatlas.org/). Log-rank p value (Mantel-Cox test) was calculated using GraphPad Prism.

(G) The indicated human cell lines were treated with human IFNγ (1 ng/mL) for 24 h and analyzed for protein expression.